This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Viewpoints in AML: Taking Progress Forward

Viewpoints in AML: Taking Progress Forward

Format

Monograph

Time to Complete

1 hour

Released

March 4, 2019

Expires

March 4, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists (0.10 CEU)

Accredited Provider

Co-provided by USF Health and Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Astellas Pharma US, Inc.

Program Description

For several decades, no new agents had been permanently approved for the treatment of acute myeloid leukemia (AML) in the frontline and relapsed/refractory (R/R) settings. In recent years, the development of cytogenetic and genetic profiles has led to a more target-specific approach to the management of AML in the induction, maintenance, and R/R phases of treatment. Those advancements have been complemented by the emergence of a vast number of new agents for patients with newly diagnosed and R/R AML that target the specific “driver” mutations of their disease—eg, FMS-like tyrosine kinase 3 (FLT3), CD33, B-cell lymphoma-2 (BCL-2), and isocitrate dehydrogenase-1 (IDH1) and IDH2. In an interview conducted by Haymarket Medical Education, Eytan M. Stein, MD, of Memorial Sloan Kettering Cancer Center in New York and Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at the H. Lee Moffitt Cancer Center in Tampa, Florida, provide insight into how far clinical research has come in the treatment of AML; their own clinical experiences; recently published data on the spectrum of targeted therapies including the FLT-3 inhibitors gilteritinib, quizartinib, and crenolanib; and the future landscape for therapeutic decision-making for patients with AML.

Intended Audience

Hematologists-oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology nurses, and advanced practitioners in oncology and specialty pharmacists (includes hospital pharmacists and pharmacy specialties such as associate directors, pharmacy directors, clinical coordinators, clinical pharmacist generalists, and clinical pharmacist specialists)

Educational Objectives

At the conclusion of this activity, participants should be better able to:


For Physicians, Nurse Practitioners, and Physician Assistants:

  • Describe the molecular pathways of FLT3, CD33, B-cell lymphoma-2 (BCL-2), and isocitrate dehydrogenase (IDH)-1 and IDH2, and the rationale behind targeted inhibition in acute myeloid leukemia (AML)
  • Recognize FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive relapsed or refractory AML patients
  • Explain the efficacy and safety of new therapies for FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive AML patients
  • Evaluate patient characteristics and preferences to develop personalized treatment plans for patients with AML to improve prognosis and outcomes

For Nurses:

  • Recognize FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive relapsed or refractory AML
  • Explain the efficacy and safety of new therapies for FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive AML patients
  • Counsel patients and caregivers regarding the efficacy and safety of FLT3-, CD33-, BCL-2–, IDH1-, and IDH2-specific therapies throughout the course of their treatment plans

For Pharmacists:

  • Recognize FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive relapsed or refractory AML
  • Explain the efficacy and safety of new therapies for FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive AML patients
  • Describe the mechanisms of action of new therapies for FLT3, CD33, BCL-2, IDH1, and IDH2 mutation-positive AML patients
  • Counsel patients with AML regarding drug-drug interactions and contraindications for specific targeted therapies

Conflict Of Interest Disclosure Policy

USF Health adheres to ACCME, ANCC, and ACPE Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity and that relevant conflict(s) of interest are resolved.

Faculty

Rami Komrokji, MD
Senior Member
Section Head, Leukemia and MDS
Vice Chair, Malignant Hematology Department
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Dr. Komrkji discloses that he is on the advisory boards of Celgene Corporation, Daiichi-Sankyo, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. He is also on the speakers’ bureau for Jazz Pharmaceuticals and Novartis Pharmaceuticals Corporation.

Eytan M. Stein, MD
Hematologic Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein discloses that he is on the advisory boards of Agios Pharmaceuticals, Astellas Pharma US, Inc., Bayer, Celgene Corporation, Daiichi-Sankyo Company Ltd., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Syros Pharmaceuticals Inc. He also receives grants/research support from Agios Pharmaceuticals, Bayer, Celgene Corporation, and Syros Pharmaceuticals Inc.

Accredited Provider Disclosures

The USF Health Office of Continuing Professional Development staff have nothing to disclose.

Planners’ and Managers’ Disclosures

Phyisican, nurse, and pharmacy planning committee members and content reviewers have nothing to disclose.

Publishing Staff Disclosures

Haymarket Medical Education staff involved in the planning of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

USF Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

A maximum of 1.00 contact hour may be earned by learners who successfully complete this continuing nursing education activity.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.00 contact hour (0.10 CEU). Universal Activity Number: 0230-9999-19-004-H01-P

Type: Knowledge-based

Designation Statement

USF Health designates this continuing education activity for 1.00 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   by ACCME-accredited providers. Physician Assistants who participate will receive a certificate of completion commensurate with the extent of their participation.

Nurse Practitioner Continuing Education
AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Astellas Pharma US, USF Health, and HME do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Astellas Pharma US, USF Health, or HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you have any questions relating to the CME accreditation of this activity, please contact USF Health at 813-224-7860 or cpdsupport@health.usf.edu.

For information about CNE accreditation of this program, please contact USF Health at 813-224-7860 or cpdsupport@health.usf.edu.

For information about the ACPE accreditation of this program, please contact USF Health at 813-224-7860 or cpdsupport@health.usf.edu.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

There are no prerequisites for this activity.

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@health.usf.edu.

Privacy Policy

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue